These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6105586)

  • 1. Addition of hepatitis-B immunoglobulin to clotting factors.
    Smit Sibinga CT; Das PC; Nieweg HO
    Lancet; 1980 Sep; 2(8193):537. PubMed ID: 6105586
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of hepatitis-B immunoglobulin to clotting factor.
    Scaroni C; Cancellieri V; Carnelli V; Moroni GA; Angeli M
    Lancet; 1980 Sep; 2(8193):537-8. PubMed ID: 6105587
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 4. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.
    Mannucci PM; Colombo M
    Thromb Haemost; 1989 Jun; 61(3):532-4. PubMed ID: 2508261
    [No Abstract]   [Full Text] [Related]  

  • 5. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 7. [Post-transfusion hepatitis and its sequelae in the treatment of hemophilia].
    Schimpf K
    Behring Inst Mitt; 1983 Aug; (73):111-7. PubMed ID: 6433878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Substitution therapy with factor 8 and factor IX preparations].
    Landbeck G
    Hamatol Bluttransfus; 1968; 5():29-42. PubMed ID: 5729465
    [No Abstract]   [Full Text] [Related]  

  • 9. Removal of hepatitis-B-virus infectivity from factor-IX complex by hepatitis-B immune-globulin. Experiments in chimpanzees.
    Tabor E; Aronson DL; Gerety RJ
    Lancet; 1980 Jul; 2(8185):68-70. PubMed ID: 6105247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion support for haemophiliacs.
    Allain JP
    Clin Haematol; 1984 Feb; 13(1):99-117. PubMed ID: 6426835
    [No Abstract]   [Full Text] [Related]  

  • 11. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatitis C virus infection in haemophiliacs.
    Lancet; 1990 Jun; 335(8703):1473-4. PubMed ID: 1972253
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO
    Beitr Infusionsther; 1989; 24():46-55. PubMed ID: 2481548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between hepatotropic viruses in patients with haemophilia.
    Lee CA; Kernoff PB; Karayiannis P; Farci P; Thomas HC
    J Hepatol; 1985; 1(4):379-84. PubMed ID: 3932510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific therapy in hemophilia.
    Hutaff LW
    N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
    [No Abstract]   [Full Text] [Related]  

  • 18. Review of the transmission of hepatitis by clotting factor concentrates.
    Tabor E
    Scand J Haematol Suppl; 1984; 40():303-8. PubMed ID: 6433456
    [No Abstract]   [Full Text] [Related]  

  • 19. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.
    Mannucci PM; Schimpf K; Brettler DB; Ciavarella N; Colombo M; Haschke F; Lechner K; Lusher J; Weissbach G
    Ann Intern Med; 1990 Jul; 113(1):27-32. PubMed ID: 2112352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidelines for working with blood in Stockholm County].
    Jordemodern; 1986 Jun; 99(6):216-7. PubMed ID: 3091547
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.